Compare AbCellera Biologics Inc (ABCL) vs MasTec Inc (MTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs MasTec Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while MasTec Inc trades at $379.86 (market cap $30.08B). The key difference: MasTec Inc is far larger — about 12.8× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | MTZ | |
|---|---|---|
Market Cap | $2.35B | $30.08B |
Sector | Health | Technology |
52-Week High | $8.12 | $437.51 |
52-Week Low | $2.78 | $168.24 |
Enterprise Value | $1.99B | $32.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MTZ trades at $380.63, up 1.93% today, with a neutral technical signal. The stock shows strong fundamental momentum, beating earnings estimates in three consecutive quarters, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of Superior Group to expand data center infrastructure capabilities, positioning the company for growth in AI-driven demand.
Outlook remains positive with 89% analyst buy ratings and a $476.62 consensus price target, implying 25% upside. Key risks include integration challenges from acquisitions and execution risks on large projects. Revenue growth is supported by infrastructure spending trends, but valuation multiples are elevated relative to industry peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
